Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors

Imatinib is a first-line drug for the treatment of gastrointestinal stromal tumors (GIST). This study aims to investigate the influence of different kinds of protein concentrations and genetic polymorphisms of metabolizing enzymes and drug transporters on unbound imatinib and its active metabolite N...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Yi, Sun, Lu-Ning, Liu, Yang-Jie, Zhang, Qiang, Xu, Jiang-Hao, Ma, Zeng-Qing, Zhang, Xue-Hui, Xu, Hao, Wang, Yong-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682687/
https://www.ncbi.nlm.nih.gov/pubmed/31417408
http://dx.doi.org/10.3389/fphar.2019.00854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682687/
https://www.ncbi.nlm.nih.gov/pubmed/31417408
http://dx.doi.org/10.3389/fphar.2019.00854

Ejemplares similares